

2011

Prevalence of human herpesvirus 8 (HHV8) and hepatitis C virus (HCV) in a rural community with high risk for blood borne infections in central China

Tiejun Zhang
Fudan University

Na He
Fudan University

Yingying Ding
Fudan University

Kay L. Crabtree
University of Nebraska-Lincoln, acrabtree2@unl.edu

Veenu Minhas
Follow this and additional works at: <http://digitalcommons.unl.edu/virologypub>
University of Nebraska-Lincoln, veenu.minhas@unmc.edu

 Part of the [Biological Phenomena, Cell Phenomena, and Immunity Commons](#), [Cell and Developmental Biology Commons](#), [Genetics and Genomics Commons](#), [Infectious Disease Commons](#), [Medical Immunology Commons](#), [Medical Pathology Commons](#), and the [Virology Commons](#)

Zhang, Tiejun; He, Na; Ding, Yingying; Crabtree, Kay L.; Minhas, Veenu; and Wood, Charles, "Prevalence of human herpesvirus 8 (HHV8) and hepatitis C virus (HCV) in a rural community with high risk for blood borne infections in central China" (2011).

Virology Papers. 350.

<http://digitalcommons.unl.edu/virologypub/350>

This Article is brought to you for free and open access by the Virology, Nebraska Center for at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Tiejun Zhang, Na He, Yingying Ding, Kay L. Crabtree, Veenu Minhas, and Charles Wood

Published in final edited form as:

Clin Microbiol Infect. 2011 March ; 17(3): 395–401. doi:10.1111/j.1469-0691.2010.03287.x.

Copyright © 2011 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. Used by permission.

Prevalence of human herpesvirus 8 (HHV8) and hepatitis C virus (HCV) in a rural community with high risk for blood borne infections in central China

Tiejun Zhang^{1,2}, Na He¹, Yingying Ding¹, Kay Crabtree², Veenu Minhas², and Charles Wood²

¹Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China and Key Laboratory of Public Health Safety (Fudan University), Ministry of Education, China

²Nebraska Center of Virology and the School of Biological Sciences, University of Nebraska-Lincoln, USA

Abstract

Former illegal blood donation in the past decade has caused HIV outbreaks in some rural areas in China. Other HIV associated virus infections, such as human herpesvirus 8 (HHV8) in such areas are still not well defined. In order to explore HHV8 and HCV seroprevalence and potential risk factors in such areas, a cross-sectional study with 305 HIV positive and 315 HIV negative subjects recruited from a rural county in Shanxi province was conducted, where illegal blood collection was reported. Interview questionnaires and serum testing were carried out with these participants. HCV and HHV8 seroprevalence were found to be higher in HIV positive than negative group (76.4% vs. 2.5%; 15.4% vs. 4.8% respectively), while the difference in HBV seroprevalence was not significant. Co-infection with HCV and HHV8 was also more prevalent in the HIV positive group. HIV status (odds ratio [OR], 2.71; 95% confidence interval [CI], 1.16–6.30) and HBV status (OR, 2.56; 95% CI: 1.14–5.75) were independently associated with HHV8 infection. HIV status (OR, 23.03; 95% CI: 9.95–53.27) and blood/plasma selling history (OR, 14.57; 95% CI: 7.49–28.23) were strongly associated with HCV infection. These findings demonstrate that both HHV8 and HCV infections are prevalent in this community. HIV infection is an important risk factor for both HHV8 and HCV infection. HBV infection is associated with HHV8 infection but not with HCV infection. It is possible that HHV8 and HBV, but not HCV, may have similar mode of transmission in this population.

Keywords

HIV; HHV8; HCV; Illegal blood donor; Seroprevalence

INTRODUCTION

Human herpesvirus 8 (HHV8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV), a member of the gamma herpesvirus family, has consistently been found to be associated with all forms of Kaposi's sarcoma (KS). It is also associated with other lymphoproliferative diseases such as primary effusion B-cell lymphomas (PELs) and multicentric Castlemans disease (MCD) [1]. HHV8 infection is not ubiquitous and the

Corresponding Authors: Na He, MD., PhD., Professor, Department of Epidemiology, School of Public Health, Fudan University, Shanghai or Charles Wood, Nebraska Center of Virology and School of Biological Sciences, University of Nebraska, Lincoln, U.S.A., cwood1@unl.edu., Phone +1-402-472-4559, Fax +1-402-472-3323.

prevalence varies in different populations but is commonly found in HIV positive individuals. HHV8 seroprevalence is generally low to moderate in western countries, ranging from 3% to 23% [2–4]. However, in sub-Saharan Africa, seroprevalence can be as high as 50% in the general population, and is even higher in the HIV positive population [5–7]. Data from Asian countries suggests that HHV8 seroprevalence is generally low [8]. Several epidemiological studies have been conducted to study the route of transmission and risk factors involved in acquiring HHV-8 infection [9–11]. While salivary transmission has emerged to be one of the major routes of transmission, a recent study conducted in Uganda has clearly demonstrated that transmission via blood transfusion can occur, albeit inefficiently [12].

In addition to HHV8, unmonitored blood transfusion may also increase the risk for acquiring hepatotropic viral infections, such as hepatitis C virus (HCV) and HBV. These viruses have been known to share similar routes of transmission and risk factors with HIV. It has also been reported that HCV coinfection is very common among HIV positive populations [13,14].

During early 1990s, illegal plasma and blood collection by commercial establishments was common in rural areas of central China, mainly as a mean for rural farmers to augment their household income [15]. Practices such as pooling of blood and re-infusion of red blood cells from donors with compatible blood types, exposed the blood donors to various blood borne pathogens including HIV. This practice had led to an outbreak of HIV in rural central China. Since the first outbreak of HCV infection among plasma donors in China in 1991, studies have shown a high seroprevalence of HCV in the illegal blood donor population [13,16]. In contrast, very little is known about HHV8 epidemiology in China, especially in this unique high risk population. A few studies on HHV8 prevalence in mainland China and in Xinjiang Uygur autonomous region in Northwestern China, which is an endemic area for KS, have been reported [17,18]. No seroprevalence studies of HHV8 have been conducted in areas of central China where a large number of illegal commercial blood/plasma donors reside, even though high prevalence of HCV and HIV has been observed in this area. The prevalence of HHV8 in this population and its correlation to HIV, HBV and HCV infection is not known.

Therefore, we conducted a cross-sectional epidemiological study to ascertain the seroprevalence of HHV8 and HCV among HIV infected patients and compared them to HIV negative individuals in a rural area in Shanxi province of Central China. To our knowledge, this is the first study to document HHV8 seroprevalence in this population. These findings will contribute to an enhanced awareness of HHV8 infection among these former blood donors.

MATERIALS AND METHODS

Study cohort and sample collection

The present study was conducted in Yun-cheng city, a rural prefecture area of Shanxi province in Central China, a community that harbors a large number of former illegal blood donors. The first case of HIV in a plasma donor for commercial gain from Yun-cheng city was reported in 1996. Since then 626 HIV/AIDS cases were reported by the end of 2004. Of these, 246 cases had died, 43 were untraceable.

A total of 620 subjects were included in the present study and all samples were collected in late 2004 through early 2005 for an observational study about the quality of life in this population. All samples were divided into two groups: a) HIV+ Group: All HIV-infected adults were recruited from the local clinic which offered free antiretroviral treatment program, as part of the national anti-HIV/AIDS campaign. Only adults participated in this

study and 305 out of 326 cases (93.6%) gave consent. The rest 21 patients were unreachable, refused to be interviewed or provide blood sample. b) HIV– Group: This group included 315 HIV uninfected individuals who were randomly selected from a local community-based adult HIV screening program from a village in the study area.

Venous blood was drawn from each study subject, coded with a unique identification number and then transferred to the laboratory within 4 hours after collection. Plasma was aliquoted and stored at -70°C . All assays were performed blindly and this study was approved by the Institutional Review Board of Fudan University, Shanghai, China.

Serological testing

a) HIV—All samples were screened with commercial enzyme-linked immunosorbent assay (ELISA; Abbott Laboratories) for HIV antibodies according to the manufacturers' protocol. Samples tested positive by ELISA were confirmed by Western blotting.

b) HCV & HBV—ELISA for HBV surface antigen (HBsAg) and anti-HCV immunoglobulin G (IgG) antibodies was conducted to determine HBV and HCV infection status, according to the manufacturers' protocol (Wantai Biomedical Co. Ltd, Beijing, China). All samples were assayed in duplicate.

c) HHV8—Plasma samples were tested by monoclonal antibody-enhanced immunofluorescence assay (IFA) as reported previously [19]. Briefly, two HHV8 serology tests were used. First, BC-3 cells, HHV8 positive and Epstein-Barr virus (EBV) negative B cell line (American Type Culture Collection, Manassas, VA.), stimulated by tetradecanoyl phorbol acetate (TPA) were fixed, permeabilized and used for monoclonal-enhanced immunofluorescence assay. Second, *Spodoptera frugiperda* clone 9 (Sf9) expressing three viral recombinant proteins, ORF73, ORF65 and K8.1, were used for testing. The procedure was similar to the BC-3 IFA. A sample was considered HHV-8-seropositive only if it was positive at a standard serum dilution of 1:40 utilizing both BC-3 and Sf9 assays. Each slide was read independently by two experienced laboratory workers.

Statistical analysis

Original questionnaire data and laboratory results were entered and managed with EpiData 3.0, and then transferred to SPSS v11.5 (Chicago, USA) for further analysis. Pearson Chi-square test and univariate logistic regression analyses were performed to explore correlates of HCV or HHV8 seropositivity. Multiple logistic regression analyses were conducted to identify risk factors for HCV or HHV8 prevalence after adjusting for potential confounders. Odds ratios (OR) with 95% confidence intervals (95% CI) were generated to determine whether a variable was independently associated with HCV or HHV8 prevalence. All *p*-values ≤ 0.05 were considered statistically significant. Mann-Whitney U test was used to assess the difference of geometric mean titers (GMTs) of HHV8 between the HIV+ and the HIV– groups. All statistical analyses were carried out using the SPSS software v11.5. Graphpad prism 5.0 (La Jolla, CA, USA) was used to construct figures.

RESULTS

Study cohort and characteristics

We enrolled 620 study participants (median age 43.0 years) from Yun-cheng city for the purposes of this study. The Han ethnic group is the major ethnic group in this province. The differences in ethnicity, age group, marital status, education and profession between the two groups were not significant. The HIV group was more likely to have multiple sex partners and individuals who had never used a condom. Seventy three percent of the HIV positive

people sold blood/plasma at least once, 16.1% had a history of receiving blood transfusions, and 11.1% had history of surgery. The major demographic characteristics of all participants (305 HIV positive and 315 HIV negative subjects) are summarized in Table 1.

HHV8 serology and associated risks factors

We conducted logistic regression analysis for risk factors associated with HHV-8 seroprevalence in this population. HHV8 seroprevalence was significantly higher in the HIV positive than negative individuals (15.4% vs. 4.8%, respectively; $P < 0.001$). The univariate analysis showed that HIV infection, HBV infection and a history of blood/plasma donation were associated with HHV8 infection. Multiple logistic regression analysis indicated that HIV and HBV infection were independently associated with HHV8 infection (OR 2.71, 95% CI: 1.16–6.30 and OR 2.56, 95% CI: 1.14–5.75, respectively) (Table 2).

HHV8 Antibody titer distribution

We also wanted to determine whether the geometric mean titer (GMT) of HHV8 antibodies differed between HIV+ and HIV- groups. Therefore, plasma from all HHV8 seropositive subjects was serially diluted and tested for IgG anti-HHV8 antibody titer. As shown in Figure 1, the GMT of HHV8 antibodies was 417.3 (95% CI: 319.5–545.1) for HIV positive group ($n=47$) and 403.2 (95% CI: 294.7–551.6) for HIV negative group ($n=15$). We did not observe any significant difference between the GMT of HHV8 antibodies between HIV infected and uninfected group (Mann-Whitney $U=357.5$, $P=0.782$).

HCV serology and associated risk factors

HCV seroprevalence was significantly higher in the HIV positive than negative group (74.4% vs. 2.5%, respectively; $P < 0.001$). In the univariate analysis, gender, condom usage, HIV status, history of selling blood/plasma and history of surgery were found to associate with HCV infection. Multivariate analysis indicated that subjects who were HIV positive (OR 23.03; 95% CI 9.95–53.27) or those who had a history of selling blood/plasma (OR 14.57; 95% CI 7.49–28.23) were more likely to be HCV seropositive than those who were HIV negative or had no history of selling blood/plasma (Table 3).

Coinfection of HBV, HCV and HHV8

The overall seroprevalence of HBV, HCV and HHV8 among the study subjects was 7.3% (45/620), 38.9% (241/620) and 10.0% (62/620), respectively. The seroprevalence of HBV, HCV and HHV8 was 7.5% (23/305), 76.4% (233/305) and 15.4% (47/305), respectively in the HIV positive group, and 7.0% (22/315), 2.5% (8/315) and 4.8% (15/315), respectively in the HIV negative group. Both HIV-infected and uninfected groups had no significant difference in prevalence of HBV ($P=0.789$) but had significant difference in prevalence of both HCV ($P < 0.001$) and HHV8 ($P < 0.001$). As shown in Table 4, 54 (17.7%) HIV-infected individuals were not coinfecting with HBV, HCV or HHV8. However, 202 (66.2%) were coinfecting with either one of the three viruses; 46 (15.1%) were coinfecting with two viruses, and 3 (1.0%) were coinfecting with all three viruses. Among the 202 HIV-infected individuals who were coinfecting with only one of the above three viruses, 187 (92.6%) were coinfecting with HCV (Table 4). Among the 46 HIV positive individuals with coinfections of two out of three viruses, 31 (67.4%) were coinfecting with HCV and HHV8. For HIV-uninfected individuals, the majority (87.3%) were negative for all three viruses. Thirty-five (11.1% of 315) were coinfecting with only one other virus, of which 51.4% were HBV-infected. Five (1.6%) were coinfecting with two other viruses (HBV, HCV and/or HHV8), and none with all three viruses (Table 4).

DISCUSSION

Given the continuing spreading of the HIV/AIDS epidemic in China, HHV8, an important opportunistic infection could become a major public health concern in China. However, little information is available for the prevalence and transmission patterns of HHV8 among the Chinese population, which can be of great importance to HHV8 prevention and control in China and to HIV/AIDS care in particular. Therefore, studies to understand the modes of HHV8 transmission and risk factors for HHV8 acquisition in China are required.

The results from this study demonstrated a higher HHV8 seroprevalence (15.4%) in HIV positive group as compared to the HIV negative group (4.8%), which is consistent with other serological studies on epidemiology of HHV8 infection in Shandong area, a neighboring province in China [20]. HHV8 prevalence varies considerably in different regions of the country. It is reported to be 19.3% to 46.6% in the general population of Xinjiang, but only between 7.3% to 16.1% in other provinces in China [17,18,20,21]. In support of other studies conducted in China, we also find that HHV8 infection is not ubiquitous in China. Compared with results from the Xinjiang area, our subjects have relatively low HHV8 prevalence. The reason for these differences may due to ethnicity, socioeconomic status, environmental characteristics and hygiene practices. Previous data have shown that both the ethnic and socioeconomic factors can influence HHV8 infection, even in the Han population in Xinjiang, which was regarded as a low risk group throughout China, although the HHV8 prevalence in the same ethnic group is higher than in other parts of China [17]. Interestingly, in our study, the HIV positive group was found to have a slightly higher anti-HHV8 antibody titer than the negative group, although the difference is not statistically significant.

As expected, we observed a very high level of coinfection with HCV in the HIV positive group (76.4%) and a much lower HCV prevalence in the HIV negative group (2.5%), which reflects the infection rate of general population in the rest of China. Since both HCV and HIV are transmitted via blood, with HCV being more infectious than HIV, it is not surprising that high HCV coinfection rate was detected in this study. Several studies on the HCV coinfection in former blood donors from other areas in China have shown similar results, demonstrating that the HCV prevalence can be as high as 78.6% to 86.3% among HIV positive subjects [13,22,23]. Our results further confirm that HCV infection is primarily blood-borne and is of public health importance to antiretroviral therapy (ART) in areas with illegal plasma/blood donors.

The current study results suggest that HIV infection was positively associated with both HHV8 and HCV infections. Furthermore, there is an association between HHV8 and HBV, but not between HHV8 and HCV coinfections. It is possible that factors associated with HBV transmission, such as close familial contact and sharing hygiene equipment are also potentially associated with HHV8 transmission. In fact, association between HHV8 and HBV infections has been reported in previous studies [12,24]. Since the HIV transmission route and blood/plasma selling history were independently associated with HCV but not with HHV8 and HBV, it is likely that HHV8 transmission route in this population is not via blood and is different from HCV. The association between HIV and HHV8 co-infection could be due to immunosuppression which rendered HIV infected individuals more susceptible to HHV8 infection. A previous study on HHV8 transmission has shown that transmission of HHV8 via blood is inefficient [25]. In fact passive transfer of HHV8 antibody was even suggested to have a protective effect in HHV8 transmission [26]. In our study no association between sexual behavior, including multiple sex patterns, condom use and HHV8 positive status was observed. This is also consistent with several previous studies demonstrating that heterosexual transmission of HHV8 is rare [27,28]. Together these

findings support the hypothesis that common routes of transmission are rarely shared by HCV and HHV8 infections in this area, which deserve further intensive research.

In conclusion, both HHV8 and HCV infections are prevalent in this former illegal blood donating community, with HIV acting as an important factor for their coinfection. Our data demonstrates that HBV infection is associated with HHV8 infection but not with HCV infection. HHV8 and HBV, but not HCV, may have similar mode of transmission in this population. A number of studies have shown that HHV8 can be detected and potentially be transmitted via saliva contact [29,30], it is possible that the saliva might play an important role in transmission in this study population. We are unable to delineate this route as saliva samples were not collected as a part of this study. Further, prospective studies on HHV8 seroprevalence and more extensive risk factor analysis, such as living arrangement, hygiene conditions and food sharing practices are needed to explore the epidemiology of HHV8 infection in this population.

Acknowledgments

TRANSPARENCY DECLARATION

This study was supported by grants from Chinese National Natural Science Foundation (30671880), Shanghai Municipal Education Committee (08ZZ02); the United States National Institutes of Health Fogarty International Center (D43 TW001492), NCI (CA75903) and NCRR COBRE grant (RR15635) to C.W.; TZ was a Fogarty Scholar.

REFERENCES

- Moore, P.; Chang, Y. Kaposi's sarcoma-associated herpesvirus. In: Knipe, D.; Howley, P.; Griffin, D.; Lamb, R.; Martin, M.; Straus, S., editors. *Field's virology*. 4th edn.. Philadelphia: Lippincott, Williams, and Wilkins; 2001. p. 2803-2833.
- Hoffman LJ, Bunker CH, Pellett PE, et al. Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. *J Infect Dis*. 2004; 189:15–20. [PubMed: 14702148]
- Laney AS, Peters JS, Manzi SM, et al. Use of a multiantigen detection algorithm for diagnosis of Kaposi's sarcoma-associated herpesvirus infection. *J Clin Microbiol*. 2006; 44:3734–3741. [PubMed: 17021103]
- Pellett PE, Wright DJ, Engels EA, et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. *Transfusion*. 2003; 43:1260–1268. [PubMed: 12919429]
- Baeten JM, Chohan BH, Lavreys L, et al. Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya. *AIDS*. 2002; 16:2073–2078. [PubMed: 12370507]
- Engels EA, Sinclair MD, Biggar RJ, et al. Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta. *Int J Cancer*. 2000; 88:1003–1008. [PubMed: 11093828]
- Rezza G, Tchangmena OB, Andreoni M, et al. Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon. *Sex Transm Dis*. 2000; 27:159–164. [PubMed: 10726650]
- Huang LM, Huang SY, Chen MY, et al. Geographical differences in human herpesvirus 8 seroepidemiology: a survey of 1,201 individuals in Asia. *J Med Virol*. 2000; 60:290–293. [PubMed: 10630961]
- de Sanjose S, Mbisa G, Perez-Alvarez S, et al. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. *J Infect Dis*. 2009; 199:1449–1456. [PubMed: 19351262]
- Goedert JJ, Charurat M, Blattner WA, et al. Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA. *AIDS*. 2003; 17:425–433. [PubMed: 12556697]
- Smith NA, Sabin CA, Gopal R, et al. Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. *J Infect Dis*. 1999; 180:600–606. [PubMed: 10438345]

12. Hladik W, Dollard SC, Mermin J, et al. Transmission of human herpesvirus 8 by blood transfusion. *N Engl J Med*. 2006; 355:1331–1338. [PubMed: 17005950]
13. Qian HZ, Vermund SH, Kaslow RA, et al. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. *AIDS*. 2006; 20:1429–1435. [PubMed: 16791018]
14. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. *Clin Infect Dis*. 2002; 34:831–837. [PubMed: 11833007]
15. Wu Z, Liu Z, Detels R. HIV-1 infection in commercial plasma donors in China. *Lancet*. 1995; 346:61–62. [PubMed: 7603178]
16. Sun YD, Meng ZD, Wang SY, et al. Epidemiologic investigation on an outbreak of hepatitis C. *Chin Med J (Engl)*. 1991; 104:975–979. [PubMed: 1782816]
17. Fu B, Sun F, Li B, et al. Seroprevalence of Kaposi's sarcoma-associated herpesvirus and risk factors in Xinjiang, China. *J Med Virol*. 2009; 81:1422–1431. [PubMed: 19551832]
18. He F, Wang X, He B, et al. Human herpesvirus 8: seroprevalence and correlates in tumor patients from Xinjiang, China. *J Med Virol*. 2007; 79:161–166. [PubMed: 17177299]
19. Minhas V, Crosby LN, Crabtree KL, et al. Development of an immunofluorescence assay using recombinant proteins expressed in insect cells to screen and confirm presence of human herpesvirus 8-specific antibodies. *Clin Vaccine Immunol*. 2008; 15:1259–1264. [PubMed: 18508931]
20. Mei Q, Ming ZW, Ping YX, et al. HHV-8 seroprevalence in blood donors and HIV-positive individuals in Shandong area, China. *J Infect*. 2007; 55:89–90. [PubMed: 17157915]
21. Zhu B, Chen Y, Xie Y, et al. Kaposi's sarcoma-associated herpesvirus (KSHV) infection: endemic strains and cladograms from immunodeficient patients in China. *J Clin Virol*. 2008; 42:7–12. [PubMed: 18164650]
22. Liu P, Xiang K, Tang H, et al. Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China. *AIDS Res Hum Retroviruses*. 2008; 24:1–6. [PubMed: 18275341]
23. Liu Z, Xing WG, Zhang YH, et al. Study on the epidemiology and HCV genotype distribution of HIV/HCV co-infection among HIV infected blood donors in China. *Zhonghua Gan Zang Bing Za Zhi*. 2006; 14:464–465. [PubMed: 16792877]
24. Zavitsanou A, Sypsa V, Petrodaskalaki M, et al. Human herpesvirus 8 (HHV-8) infection in healthy urban employees from Greece: seroprevalence and associated factors. *J Med Virol*. 2007; 79:591–596. [PubMed: 17385692]
25. Cannon MJ, Operskalski EA, Mosley JW, et al. Lack of evidence for human herpesvirus-8 transmission via blood transfusion in a historical US cohort. *J Infect Dis*. 2009; 199:1592–1598. [PubMed: 19385734]
26. Fowlkes AL, Brown C, Amin MM, et al. Quantitation of human herpesvirus 8 (HHV-8) antibody in patients transfused with HHV-8-seropositive blood. *Transfusion*. 2009; 49:2208–2213. [PubMed: 19555417]
27. Campbell TB, Borok M, Ndemera B, et al. Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe. *Clin Infect Dis*. 2009; 48:1601–1608. [PubMed: 19400749]
28. Malope BI, MacPhail P, Mbisa G, et al. No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population. *Aids*. 2008; 22:519–526. [PubMed: 18301065]
29. Brayfield BP, Kankasa C, West JT, et al. Distribution of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 in maternal saliva and breast milk in Zambia: implications for transmission. *J Infect Dis*. 2004; 189:2260–2270. [PubMed: 15181574]
30. Plancoulaine S, Abel L, van Beveren M, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. *Lancet*. 2000; 356:1062–1065. [PubMed: 11009141]




Figure 1.

GMT of HHV8 antibodies in seropositive participants in the HIV positive and negative groups.

*Antibody titers were determined by IFA based on BC3 slides. GMT for both groups were calculated and compared. (Mann-Whitney $U=357.5$, $P=0.782$)

Table 1

Characteristics of study participants.

	HIV + Group	HIV- Group	Total
Gender (P=0.002)			
Male	165 (54.1%)	132 (41.9%)	297 (47.9%)
Female	140 (45.9%)	183 (58.1%)	323 (52.1%)
Ethnicity (P=0.078)			
Han	302 (99.0%)	315 (100.0%)	617 (99.5%)
Others	3 (0.9%)	0 (0%)	3 (0.5%)
Age group (P=0.029)			
19-29	10 (3.3%)	18 (5.7%)	28 (4.5%)
30-49	224 (73.4%)	201 (63.8%)	425 (68.6%)
50+	71 (23.3%)	96 (30.5%)	167 (26.9%)
Marital status (P=0.720)			
Married	292 (95.7%)	302 (95.9%)	594 (95.8%)
Single	4 (1.3%)	6 (1.9%)	10 (1.6%)
Divorced/Widowed	9 (3.0%)	7 (2.2%)	16 (2.6%)
Education (P=0.019)			
Illiterate	26 (8.5%)	14 (4.4%)	40 (6.5%)
Primary school	109 (35.7%)	111 (35.3%)	220 (35.5%)
Middle school	154 (50.5%)	156 (49.5%)	310 (50.0%)
High school or higher	16 (5.2%)	34 (10.8%)	50 (8.1%)
Farmer (P=0.019)			
Yes	290 (95.1%)	284 (90.2%)	574 (92.6%)
No	15 (5.0%)	31 (9.1%)	46 (7.4%)
Multiple sex partners (P=0.012)			
Yes	16 (5.2%)	5 (1.6%)	21 (3.4%)
No	289 (94.8%)	310 (98.4%)	599 (96.6%)
Ever used condoms (P<0.001)			
Yes	256 (83.9%)	290 (93.8%)	546 (88.9%)
No	49 (16.1%)	19 (6.0%)	68 (11.1%)
Ever had blood transfusion (P<0.001)			
Yes	49 (16.1%)	16 (5.1%)	65 (10.5%)
No	256 (83.9%)	299 (94.9%)	555 (89.5%)
Ever donated blood/plasma (P<0.001)			
Yes	223 (73.1%)	0 (0%)	223 (35.9%)
No	82 (26.9%)	315 (100%)	397 (64.1%)
Ever had a surgery (P<0.001)			
Yes	34 (11.1%)	12 (3.8%)	46 (7.5%)
No	271 (88.9%)	303 (96.2%)	574 (92.5%)

Table 2

Seroprevalence and correlates of HHV8 infection among the study subjects

Characteristics/Risk factor	Positive/Total (%)	Univariate analysis		Multivariate analysis	
		OR (95%CI)	p-value	OR (95%CI)*	p-value
Gender					
Male	26/297 (8.8%)	1.00			
Female	36/323 (11.1%)	1.31 (0.77–2.22)	0.323		
Age group					
19–29	2/28 (7.1%)	1.00			
30–49	46/425 (10.8%)	1.58 (0.36–6.86)	0.543		
50+	14/167 (8.4%)	1.19 (0.26–5.54)	0.825		
Education					
Illiterate	4/40 (10.0%)	1.00			
Elementary school	26/220 (11.8%)	1.21 (0.40–3.66)	0.741		
Middle school	28/310 (9.0%)	0.89 (0.30–2.69)	0.842		
High school or higher	4/50 (8.0%)	0.78 (0.18–3.35)	0.741		
Farmer					
Yes	58/574 (10.1%)	1.00			
No	4/46 (8.7%)	0.85 (0.29–2.45)	0.759		
Ever married					
Yes	61/610 (10.0%)	1.00			
No	1/10 (10.0%)	1.00 (0.12–8.03)	1.000		
Multiple sex partners					
Yes	2/21 (9.5%)	0.95 (0.22–4.16)	0.941		
No	60/599 (10.0%)	1.00			
Ever used condoms					
Yes	56/546 (10.3%)	1.18 (0.49–2.85)	0.712		
No	6/68 (8.8%)	1.00			
HIV infection status					
Positive	50/305 (15.4%)	3.64 (1.99–6.67)	<0.001	2.71 (1.16–6.30)	0.021**
Negative	15/315 (4.8%)	1.00		1.00	

Characteristics/Risk factor	Positive/Total (%)	Univariate analysis		Multivariate analysis	
		OR (95%CI)	p-value	OR (95%CI)*	p-value
HBsAg					
Positive	9/45 (20.0%)	2.46 (1.12–5.39)	0.024	2.56 (1.14–5.75)	0.022**
Negative	53/575 (9.2%)	1.00		1.00	
Ever had blood transfusion					
Yes	8/685 (12.3%)	1.30 (0.59–2.87)	0.513		
No	54/555 (9.7%)	1.00			
Ever donated blood/plasma					
Yes	37/223 (16.6%)	2.96 (1.73–5.60)	<0.001	1.493 (0.71–3.18)	0.299
No	25/397 (6.3%)	1.00		1.00	

* Odds ratio and p-value obtained by multiple logistic regression model, which was adjusted for all demographic variables listed in this table. 95% CI: 95% confidence interval

Table 3

Seroprevalence and correlates of HCV infection among the study subjects

Characteristics/Risk factor	Positive/Total (%)	Univariate analysis		Multivariate analysis	
		OR 95%CI	p-value	OR (95%CI)*	p-value
Gender					
Male	142/297 (47.8%)	1.00		1.00	
Female	99/323 (30.7%)	0.48 (0.35–0.67)	<0.001	0.82 (0.45–1.50)	0.52
Age group					
19–29	7/28 (25.0%)	1.00			
30–49	167/425 (39.3%)	1.94 (0.81–4.67)	0.138		
50–	67/167 (40.1%)	2.01 (0.81–4.99)	0.133		
Education					
Illiterate	19/40 (47.5%)	1.00			
Elementary school	91/220 (41.4%)	0.78 (0.40–1.53)	0.471		
Middle school	123/310 (39.7%)	0.73 (0.38–1.41)	0.344		
High school or higher	8/50 (16.0%)	0.22 (0.08–0.56)	0.002		
Farmer					
Yes	230/574 (40.1%)	1.00		1.00	
No	11/46 (23.9%)	0.47 (0.23–0.94)	0.034	0.61 (0.17–2.17)	0.45
Ever married					
Yes	237/610 (38.9%)	1.00			
No	4/10 (40.0%)	1.05 (0.29–3.76)	0.941		
Multiple sex partners					
Yes	10/21 (47.6%)	1.45 (0.61–3.46)	0.405		
No	231/599 (38.6%)	1.00			
Ever used condoms					
Yes	198/546 (36.3%)	0.33 (0.20–0.56)	0.001	0.69 (0.28–1.76)	0.44
No	43/68 (63.2%)	1.00		1.00	
HIV infection status					
Positive	233/305 (76.4%)	124.19 (58.66–262.91)	<0.001	23.03 (9.95–53.27)	<0.001**
Negative	8/315 (2.5%)	1.00		1.00	

Characteristics/Risk factor	Positive/Total (%)	Univariate analysis		Multivariate analysis	
		OR	95%CI	OR (95%CI)*	p-value
HBsAg					
Positive	16/45 (35.6%)	0.86	(0.46–1.62)		0.636
Negative	225/575 (39.1%)	1.00			
Ever had blood transfusion					
Yes	28/65 (43.1%)	1.22	(0.72–2.04)		0.463
No	213/555 (38.4%)	1.00			
Ever donated blood/plasma					
Yes	202/223 (90.2%)	88.29	(50.54–154.20)	14.57 (7.49–28.23)	<0.001 ^{**}
No	39/397 (9.8%)	1.00		1.00	

^{**} Odds ratio and p-value obtained by multiple logistic regression model, which was adjusted for all demographic variables listed in this table. 95% CI: 95% confidence interval

Table 4

Summary of infection by HBV, HCV and HHV8 in HIV positive and negative groups

Co-infected with	HIV+ Group (N=305)		HIV- Group (N=315)	
	No.	Prevalence (%)	No.	Prevalence (%)
None	54*	17.7	275	87.3
Single virus only				
HBV	5*	1.6	18	5.7
HCV	187*	61.3	6	1.9
HHV8	10*	3.3	11	3.5
Dual viruses				
HBV+HCV	12*	3.9	1	0.3
HBV+HHV8	3*	1.0	3	1.0
HCV+HHV8	31*	10.2	1	0.3
Triple viruses				
HBV+HCV+HHV8	3*	1.0	0	0

* These infections are HHV8, HCV or HBV plus HIV